Citations

Clear

959 citation(s) found for "Service, F J".

Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study
Lehrer, Eric J. , Gurewitz, Jason , Bernstein, Kenneth , Patel, Dev , Niranjan, Ajay , Wei, Zhishuo , Lunsford, L. Dade , Malouff, Timothy D. , Patel, Samir , Bonney, Phillip A. , Hwang, Lindsay , Yu, Cheng , Zada, Gabriel , Mathieu, David , Trudel, Claire, Prasad, Rahul N. , Sharma, Sonam , Fakhoury, Kareem , Rusthoven, Chad G. , Deibert, Christopher P., Picozzi, Piero , Franzini, Andrea , Attuati, Luca , Lee, Cheng‐Chia , Ahluwalia, Manmeet S. , Sheehan, Jason P. , Trifiletti, Daniel M , Mathieu, David , Ahluwalia, Manmeet S , Patel, Dev, Kondziolka, Douglas , Ruiz-García, Henry , Palmer, Joshua D. , Jones, Brianna M. , Yang, Huai‐Che , Trifiletti, Daniel M.

Mayo Clinic

Cancer | January 25, 2022 | Volume: 128 | Issue: 7 | Pages: 1429-1438

10.1002/cncr.34087 | PMID 35077586 Get It

BACKGROUNDPatients with renal cell carcinoma (RCC) brain metastases are frequently treated with immune checkpoint inhibitors (ICIs) and stereotactic radiosurgery (SRS). However, data reporting on the risk of developing radiation necrosis (RN) are limited.METHODSRN rates were compared for concurrent therapy (ICI/SRS administration within 4 weeks of one another) and nonconcurrent therapy with the χ2 test. Univariable logistic regression was used to identify factors associated with developing RN.RESULTSFifty patients (23 concurrent and 27 nonconcurrent) with 395 brain metastases were analyzed. The median follow‐up was 12.1 months; the median age was 65 years. The median margin dose was 20 Gy, and 4% underwent prior whole‐brain radiation therapy (WBRT). The median treated tumor volume was 3.32 cm3 (range, 0.06‐42.38 cm3); the median volume of normal brain tissue receiving a dose of 12 Gy or higher (V12 Gy) was 8.42 cm3 (range, 0.27‐111.22 cm3). Any‐grade RN occurred in 17.4% and 22.2% in the concurrent and nonconcurrent groups, respectively (P = .67). Symptomatic RN occurred in 4.3% and 14.8% in the concurrent and nonconcurrent groups, respectively (P = .23). Increased tumor volume during SRS (odds ratio [OR], 1.08; 95% confidence interval [CI], 1.01‐1.19; P = .04) was associated with developing RN, although V12 Gy (OR, 1.03; 95% CI, 0.99‐1.06; P = .06), concurrent therapy (OR, 0.74; 95% CI, 0.17‐2.30; P = .76), prior WBRT, and ICI agents were not statistically significant.CONCLUSIONSSymptomatic RN occurs in a minority of patients with RCC brain metastases treated with ICI/SRS. The majority of events were grade 1 to 3 and were managed medically. Concurrent ICI/SRS does not appear to increase this risk. Attempts to improve dose conformality (reduce V12) may be the most successful mitigation strategy in single‐fraction SRS.
Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
León, José de , Schoretsanitis, Georgios , Smith, Robert L. , Molden, Espen , Solismaa, Anssi , Seppälä, Niko , Kopeček, Miloslav , Švancer, Patrik , Olmos, I. Cánovas , Ricciardi, Carina , Iglesias-Alonso, Ana , Ruan, Can‐Jun , Wang, Chuanyue , Wang, Gang , Tang, Yi‐lang , Kim, Yong Sik , Kim, Se Hyun , Jung–Cook, Helgi , Nielsen, Jimmi , Verdoux, Hélène , Quilès, Clélia , Cohen, Dan , Schulte, Peter F.J. , Chopra, Nitin , McCollum, Betsy , Shelton, Charles , Cotes, Robert O. , Kaithi, Arun R., Farooq, Saeed , Ng, Chee H. , Bilbily, John , Lana, Fernando , Rădulescu, Flavian Ștefan , Seifritz, Erich , Every‐Palmer, Susanna , Bebawi, Emmanuel , Kelly, Deanna L. , Lazáry, Judit , Torres, Rafael , Yécora, Agustín, Berardis, Domenico De , Adebayo, Richard A. , Fountoulakis, Konstantinos Ν. , Ayub, Muhammad , Silva, Alzira , Bonelli, Raphael M., Crespo‐Facorro, Benedicto , Temmingh, Henk , Decloedt, Eric , Pedro, Maria Rosel , Gründer, Gerhard , Čelofiga, Andreja , Ristić, Dragana Ignjatović , Elkis, Hélio , Siskind, Dan , Masmoudi, R. , Saffian, Shamin Mohd , Buckley, P.F. , Freudenreich, Oliver , Müller, Daniel J. , de Leon, Jose , Olmos, Ismael , Iglesias-Garcia, Celso , Iglesias-Alonso, Ana , Spina, Edoardo , Ruan, Can-Jun , Wang, Chuan-Yue , Tang, Yi-Lang , Lin, Shih-Ku , Lane, Hsien-Yuan , Kim, Yong Sik , Kim, Se Hyun , Rajkumar, Anto P , González-Esquivel, Dinora F , Jung-Cook, Helgi , Baptista, Trino , Rohde, Christopher , Nielsen, Jimmi , Verdoux, Hélène , Quiles, Clelia , Sanz, Emilio J , De Las Cuevas, Carlos , Cohen, Dan , Schulte, Peter F J , Ertuğrul, Aygün , Anıl Yağcıoğlu, A Elif , Chopra, Nitin , McCollum, Betsy , Shelton, Charles , Cotes, Robert O , Kane, John M , Farooq, Saeed , Ng, Chee H , Bilbily, John , Hiemke, Christoph , López-Jaramillo, Carlos , McGrane, Ian , Lana, Fernando , Eap, Chin B , Every-Palmer, Susanna , Bousman, Chad A , Bebawi, Emmanuel , Bhattacharya, Rahul , Kelly, Deanna L , Otsuka, Yuji , Lazary, Judit , Motuca, Mariano , Chan, Sherry K W , Zolezzi, Monica , Ouanes, Sami , De Berardis, Domenico , Grover, Sandeep , Procyshyn, Ric M , Adebayo, Richard A , Kirilochev, Oleg O , Soloviev, Andrey , Fountoulakis, Konstantinos N , Wilkowska, Alina , Cubała, Wiesław J , Ayub, Muhammad , Silva, Alzira , Villagrán-Moreno, José M , Crespo-Facorro, Benedicto , Temmingh, Henk , Decloedt, Eric , Pedro, Maria R , Takeuchi, Hiroyoshi , Tsukahara, Masaru , Gründer, Gerhard , Sagud, Marina , Celofiga, Andreja , Ignjatovic Ristic, Dragana , Ortiz, Bruno B , Elkis, Helio , Pacheco Palha, António J , LLerena, Adrián , Fernandez-Egea, Emilio , Siskind, Dan , Weizman, Abraham , Masmoudi, Rim , Mohd Saffian, Shamin , Leung, Jonathan G , Buckley, Peter F , Marder, Stephen R , Citrome, Leslie , Freudenreich, Oliver , Correll, Christoph Ulrich , Müller, Daniel J , Kopecek, Miloslav , Schoretsanitis, Georgios , García, Celso Iglesias , Rajkumar, Anto P. , González‐Esquivel, Dinora F. , Rohde, Christopher , Sanz, Emílio J. , Cuevas, Carlos De las , Yağcıoğlu, A. Elif Anıl , Kane, John M. , Hiemke, Christoph , López‐Jaramillo, Carlos , McGrane, Ian R. , Arrojo, Manuel , Bousman, Chad , Bhattacharya, Rahul , Motuca, Mariano , Chan, Sherry Kit Wa , Кирилочев, О.О. , Soloviev, A. G. , Wilkowska, Alina , Cubała, Wiesław Jerzy , Tsukahara, Masaru , Ortiz, Bruno Bertolucci , LLerena, Adrián , Leung, Jonathan G. , Citrome, Leslie

Mayo Clinic

Pharmacopsychiatry | January 20, 2022 | Volume: 55 | Issue: 02 | Pages: e1-e1

10.1055/a-1737-1527 | PMID 35052001 Get It

Cardiotoxicity from Capecitabine Chemotherapy: Prospective Study of Incidence at Rest and During Physical Exercise
Lestuzzi, Chiara , Tartuferi, Lucia, Viel, E, Angelis, Giulia De , Lonardi, Sara , Innocente, R. , Herrmann, Joerg , Bidoli, Ettore , Lonardi, Sara , Bergamo, Francesca , Guglielmi, Alessandra , Sinagra, Gianfranco , Herrmann, Joerg , Stolfo, Davide , Paoli, Antonino De , Banzato, Alberto , Buonadonna, Angela , Berretta, Massimiliano , Bergamo, Francesca

Mayo Clinic

The Oncologist | January 14, 2022 | Volume: 27 | Issue: 2 | Pages: e158-e167

10.1093/oncolo/oyab035 | PMID 35641220 Get It

AbstractBackgroundPhysical activity may increase the risk of cardiotoxicity (myocardial ischemia, major arrhythmias) of 5-Fluorouracil, but this risk has never been investigated for its prodrug capecitabine.Patients and MethodsOne hundred and ninety-two consecutive patients undergoing capecitabine chemotherapy from December 1, 2010 through July 31, 2016 were prospectively evaluated. The baseline evaluation included electrocardiography (ECG) and echocardiography (2DE); a follow-up evaluation, including ECG and exercise stress testing (2DE in case of ECG abnormalities), was done after ≥10 days of treatment. Cardiotoxicity was suspected from ischemic ECG changes, new kinetic abnormalities at 2DE, Lown classification ≥2 ventricular arrhythmia, symptomatic arrhythmias, or positive stress test, and confirmed by a negative stress test after capecitabine washout.ResultsCardiotoxicity was diagnosed in 32 patients (16.7%): six at rest and 26 during exercise. All 32 patients had ECG abnormalities: ST-segment changes (24 patients), negative T-waves (2) and/or arrhythmias: ventricular arrhythmias (14 cases), supraventricular tachycardia (2), complete heart block (1). Eight patients had typical symptoms, 6 had atypical symptoms, 1 had syncope, 17 (53%) were asymptomatic. Cardiotoxicity was more common in patients with atypical symptoms during daily life (OR = 15.7) and in those on a therapeutic schedule of 5 days/week (OR = 9.44).ConclusionCapecitabine cardiotoxicity is frequent, and often elicited by physical effort. Oncologists, cardiologists, and general practitioners should be aware of this risk. Active cardiotoxicity surveillance with ECG (and echocardiogram and/or stress testing in suspected cases) during therapy is recommended.Clinical Trials registration numberCRO-2010-17.
Clinical, histological and molecular profiling of different stages of alcohol-related liver disease
Ventura‐Cots, Meritxell , Argemí, Josepmaria , Jones, Patricia D. , Lackner, Carolin , Hag, Mohamed El , Abraldeṣ, Juan G. , Alvarado, Edilmar, Clemente, Ana , Ravi, Samhita , Altamirano, José , Barace, Sergio , Caballería, Juan , Carvalhana, Sofia , Cortez‐Pinto, Helena , Costa, Adília, Degré, Delphine, Fernández‐Carrillo, Carlos , García–Tsao, Guadalupe , Koskinas, John , Lanthier, Nicolas , Lozano, Juan José , Lucey, Michael R. , Masson, Steven , Mathurin, Philippe, Miquel, Rosa , Moreno, Christophe , Mounajjed, Taofic, Sancho‐Bru, Pau , Sands, R. Warren , Szafranska, Justyna , Verset, Laurine , Schnabl, Bern, Shah, Vijay H. , Shawcross, Debbie L. , Verna, Elizabeth C. , Vargas, Vı́ctor , Woosley, John T. , Mueller, Sebastian , Stärkel, Peter , Mathurin, Philippe , Alboraie, Mohamed , Bosques, Francisco , Lanthier, Nicolas , Louvet, Alexandre , Masson, Steven , Mathurin, Philippe , Sancho-Bru, Pau , Shah, Vijay, Shawcross, Debbie Lindsay , Bataller, Ramon A , Cortez-Pinto, Helena , Vargas, Victor , Ventura Cots, Meritxell , Abraldes, Juan G , Alves, António , Brown, Robert S. , Cabezas, Joaquín , Ganne‐Carrié, Nathalie , Genescà, Joan , Louvet, Alexandre , Méndez‐Sánchez, Nahúm , Òdena, Gemma , Kim, Won Kyum , Schnabl, Bernd , Sempoux, Christine , Stauber, Rudolf E , Straub, Beate Katharina , Tiniakos, Dina , Trépo, Eric , Villanueva, Càndid , Ziol, Marianne

Mayo Clinic

Gut | January 6, 2022 | Volume: 71 | Issue: 9 | Pages: 1856-1866

10.1136/gutjnl-2021-324295 | PMID 34992134 Get It

Objective Alcohol-related liver disease (ALD) ranges from never-decompensated ALD (ndALD) to the life-threatening decompensated phenotype, known as alcohol-related hepatitis (AH). A multidimensional study of the clinical, histological and molecular features of these subtypes is lacking. Design Two large cohorts of patients were recruited in an international, observational multicentre study: a retrospective cohort of patients with ndALD (n=110) and a prospective cohort of patients with AH (n=225). Clinical, analytical, immunohistochemistry and hepatic RNA microarray analysis of both disease phenotypes were performed. Results Age and mean alcohol intake were similar in both groups. AH patients had greater aspartate amino transferase/alanine amino transferase ratio and lower gamma-glutamyl transferase levels than in ndALD patients. Patients with AH demonstrated profound liver failure and increased mortality. One-year mortality was 10% in ndALD and 50% in AH. Histologically, steatosis grade, ballooning and pericellular fibrosis were similar in both groups, while advanced fibrosis, Mallory-Denk bodies, bilirubinostasis, severe neutrophil infiltration and ductular reaction were more frequent among AH patients. Transcriptome analysis revealed a profound gene dysregulation within both phenotypes when compare to controls. While ndALD was characterised by deregulated expression of genes involved in matrisome and immune response, the development of AH resulted in a marked deregulation of genes involved in hepatocyte reprogramming and bile acid metabolism. Conclusions Despite comparable alcohol intake, AH patients presented with worse liver function compared with ndALD patients. Bilirubinostasis, severe fibrosis and ductular reaction were prominent features of AH. AH patients exhibited a more profound deregulation of gene expression compared with ndALD patients.
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors
Rahman, Zaid Abdel , Grenet, Justin , Boisclair, Stéphanie , Bewersdorf, Jan Philipp , Barth, Dylan , Fraga, Martina , Bixby, Dale L. , Zeidan, Amer M. , Desai, Pankil , Mannis, Gabriel N. , Deutsch, Yehuda E., Dinner, Shira, Frankfurt, Olga, Litzow, Mark R. , Al‐Kali, Aref , Foran, James M. , Sproat, Lisa Z., Jovanovic, Borko, Perl, Alexander E. , Altman, Jessica K. , Rahman, Zaid H. Abdel , Numan, Yazan , Abdel Rahman, Zaid, Bewersdorf, Jan P , Yilmaz, Musa , Litzow, Mark R. , Daver, Naval , Altman, Jessica K , Abdel Rahman, Zaid H , Zeidan, Amer M , Collins, Cailin T. , Yılmaz, Musa , Abaza, Yasmin , Daver, Naval

Mayo Clinic

American Journal of Hematology | January 4, 2022 | Volume: 97 | Issue: 3 | Pages: 322-328

10.1002/ajh.26447 | PMID 34981560 Get It

AbstractGilteritinib is approved for the treatment of relapsed/refractory (R/R) acute myeloid leukemia (AML) with an FLT3‐mutation (FLT3mut+). However, the gilteritinib phase 3 ADMIRAL study (Perl et al NEJM 2019) was conducted prior to widespread adoption of either midostaurin as a component of standard intensive induction and consolidation or posttransplant FLT3 inhibitor maintenance. We performed a retrospective analysis using data from 11 US centers and where we identified 113 patients who received gilteritinib alone or as combination therapy for the treatment of R/R FLT3mut+ AML. The composite complete remission (CR) rate (CRc, defined as CR + CRi + CR with incomplete platelet recovery [CRp]) was 48.7% (n = 55). The CRc rate after treatment with gilteritinib in patients who were treated with only prior 7+3 and midostaurin with or without consolidation was 58% with a median survival of 7.8 months. Survival was longest in patients who obtained a CR, particularly a cMRD (clinical minimal or measurable residual disease) negative response; this remained significant after censoring at the time of stem cell transplant. The mitogen‐activated protein kinase pathway activating mutations that are known for gilteritinib resistance (NRAS, KRAS, and PTPN11) had lower CRc (35% vs. 60.5%) and lower median overall survival than patients' whose leukemia did not express these mutations (4.9 months vs. 7.8 months) (HR 2.4; 95% CI 1. 5.4) p value <.01.
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study
Gregory, Gareth P. , Kumar, Shaji , Mahadevan, Daruka , Walker, Patricia , Wagner‐Johnston, Nina D. , Bannerji, Rajat , Bhutani, Divaya , Chang, Julie , Hernandez‐Ilizaliturri, Francisco J. , Klein, Andreas K. , Pagel, John M. , Rybka, Witold B. , Mohrbacher, Anne, Huang, Mo , Farooqui, Mohammed, Marinello, Patricia, Wagner-Johnston, Nina , Bannerji, Rajat , Bhutani, Divaya , Rybka, Witold , Yee, Andrew J , Huang, Mo , Quach, Hang , Wang, Ding , Escobar, Carolina, Mohrbacher, Ann M., Quach, Hang

Mayo Clinic

Blood Advances | December 31, 2021 | Volume: 6 | Issue: 4 | Pages: 1232-1242

10.1182/bloodadvances.2021005872 | PMID 34972202 Get It

AbstractPreclinical data demonstrated that combining an anti–programmed cell death 1 (PD-1) inhibitor with a cyclin-dependent kinase 9 (CDK9) inhibitor provided enhanced antitumor activity with no significant toxicities, suggesting this combination may be a potential therapeutic option. The multicohort, phase 1 KEYNOTE-155 study evaluated the safety and antitumor activity of the PD-1 inhibitor pembrolizumab plus the CDK9 inhibitor dinaciclib in patients with relapsed or refractory (rr) chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM). Patients enrolled were ≥18 years of age with a confirmed diagnosis of CLL, DLBCL, or MM. The study included 2 phases: a dose-evaluation phase to determine dose-limiting toxicities and a signal-detection phase. Patients received pembrolizumab 200 mg every 3 weeks plus dinaciclib 7 mg/m2 on day 1 and 10 mg/m2 on day 8 of cycle 1 and 14 mg/m2 on days 1 and 8 of cycles 2 and later. Primary endpoint was safety, and a key secondary endpoint was objective response rate (ORR). Seventy-two patients were enrolled and received ≥1 dose of study treatment (CLL, n = 17; DLBCL, n = 38; MM, n = 17). Pembrolizumab plus dinaciclib was generally well tolerated and produced no unexpected toxicities. The ORRs were 29.4% (5/17, rrCLL), 21.1% (8/38, rrDLBCL), and 0% (0/17, rrMM), respectively. At data cutoff, all 72 patients had discontinued treatment, 38 (52.8%) because of progressive disease. These findings demonstrate activity with combination pembrolizumab plus dinaciclib and suggest that a careful and comprehensive approach to explore anti–PD-1 and CDK9 inhibitor combinations is warranted. This trial was registered at www.clinicaltrials.gov as NCT02684617.
Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019
Kocarnik, Jonathan , Compton, Kelly, Dean, Frances , Fu, Weijia , Gaw, Brian, Harvey, James , Henrikson, Hannah , Lu, Dan , Pennini, Alyssa, Xu, Rixing, Ababneh, Emad , Abbasi‐Kangevari, Mohsen , Abbastabar, Hedayat , Abd‐Elsalam, Sherief , Abedi, Aidin , Abidi, Hassan , Abolhassani, Hassan , Adedeji, Isaac Akinkunmi , Advani, Shailesh M, Aghaali, Mohammad , Ahmad, Tauseef , Rashid, Tarik A. , Salih, Yusra Ahmed , Aklilu, Addis , Akram, Tayyaba , Akunna, Chisom Joyqueenet , Hamad, Hanadi Al , Alahdab, Fares , Alimohamadi, Yousef, Alipour, Vahid, Alkhayyat, Motasem , Almasri, Nihad A. , Al‐Maweri, Sadeq Ali , Almustanyir, Sami , Alonso, Nivaldo , Alvis‐Guzmán, Nelson , Amu, Hubert , Ansari, Fereshteh, Antwi, Maxwell Hubert , Anvari, Davood , Anyasodor, Anayochukwu Edward , Aqeel, Muhammad , Arabloo, Jalal , Aremu, Olatunde , Ariffin, Hany , Aripov, Timur , Arshad, Muhammad , Artaman, Al, Arulappan, Judie , Jafarabadi, Mohammad Asghari , Ashraf, Tahira , Atorkey, Prince , Ausloos, Marcel , Awedew, Atalel Fentahun , Quintanilla, Beatriz Paulina Ayala , Ayenew, Temesgen , Azab, Mohammed A. , Azadnajafabad, Sina , Jafari, Amirhossein Azari , Azarian, Ghasem , Badiye, Ashish , Bahadory, Saeed , Baig, Atif Amin , Baker, Jennifer L. , Balakrishnan, Senthilkumar , Bärnighausen, Till , Barone‐Adesi, Francesco , Barrow, Amadou , Belgaumi, Uzma , Bezabhe, Woldesellassie, Bezabih, Yihienew Mequanint , Bhagat, Devidas S. , Bhagavathula, Akshaya Srikanth , Bhardwaj, Nikha , Bhaskar, Sonu , Bhojaraja, Vijayalakshmi S, Bibi, Sadia , Bijani, Ali , Bisignano, Catherine, Bolarinwa, Obasanjo Afolabi , Bolla, Srinivasa Rao , Braithwaite, Dejana , Brar, Amanpreet , Brenner, Hermann , Bustamante-Teixeira, Maria Teresa , Butt, Nadeem Shafique , Butt, Zahid A , Santos, Florentino Luciano Caetano dos , Cao, Yin , Carreras, Giulia , Catalá-López, Ferrán , Cembranel, Francieli , Cerin, Ester , Cernigliaro, Achille , Chakinala, Raja Chandra , Chattu, Soosanna Kumary , Chattu, Vijay Kumar , Chaturvedi, Pankaj, Chimed‐Ochir, Odgerel , Cho, Daniel , Chu, Dinh‐Toi , Conde, João , Cortés, Sandra , Cortesi, Paolo Angelo, Costa, Vera Marisa , Cunha, Amanda Ramos da , Dadras, Omid , Dagnew, Amare Belachew , Dandona, Lalit , Dandona, Rakhi , Hoz, Fernando de la , Dhamnetiya, Deepak , Dhimal, Mandira Lamichhane , Díaz, Daniel , Djalalinia, Shirin , Doaei, Saeid , Dorostkar, Fariba, Driscoll, Tim , Ebrahimi, Hedyeh , Eftekharzadeh, Sahar , Tantawi, Maha El , El‐Abid, Hassan , Elbarazi, Iffat , Elhabashy, Hala Rashad , Elhadi, Muhammed , Eshrati, Babak, Esmaeilzadeh, Firooz , Etemadi, Arash , Ezzikouri, Sayeh , Faisaluddin, Mohammed, Fares, Jawad , Farzadfar, Farshad , Feroze, Abdullah , Desideri, Lorenzo Ferro , Fischer, Florian , Fisher, James L. , Fukumoto, Takeshi , Gad, Mohamed M. , Fonseca, Mariana Gaspar, Obsa, Abera Getachew, Ghafourifard, Mansour , Ghashghaee, Ahmad , Ghith, Nermin , Gholamalizadeh, Maryam , Gilani, Syed Amir , Gizaw, Abraham Tamirat , Glasbey, James , Golechha, Mahaveer , Goleij, Pouya , Gopalani, Sameer Vali , Gorini, Giuseppe , Goudarzi, Houman , Gubari, Mohammed Ibrahim Mohialdeen , Guerra, Maximiliano Ribeiro, Guha, Avirup , Gunasekera, Sanjeeva , Gupta, Bhawna , Gupta, Vivek , Gutiérrez, Reyna Alma, Hafezi‐Nejad, Nima , Haider, Mohammad Rifat , Hameed, Sajid , Hanif, Asif , Haque, Shafiul , Harlianto, Netanja I. , Hasaballah, Ahmed I , Hay, Simon I , Heidari, Golnaz , Herrera-Serna, Brenda Yuliana , Herţeliu, Claudiu , Hezam, Kamal , Hossain, Mohammad Bellal , Hosseini, Mohammad‐Salar , Hosseini, Mostafa, Hosseinzadeh, Mehdi , Hostiuc, Mihaela , Househ, Mowafa , Hsaïri, Mohamed, Huang, Junjie , Hugo, Fernando Neves , Hussain, Rabia , Hussein, Nawfal R , Hwang, Bing‐Fang , Ibitoye, Segun Emmanuel , Ida, Fidelia , Ikuta, Kevin S , Ilić, Irena , Irham, Lalu Muhammad , Islam, Jessica Y. , Islam, Sheikh Mohammed Shariful , Ismail, Nahlah Elkudssiah , Isola, Gaetano , Iwagami, Masao , Jacob, Louis , Jain, Vardhmaan , Jakovljević, Mihajlo, Javaheri, Tahereh , Jayaram, Shubha, Jha, Ravi Prakash , Jonas, Jost B, Joó, Tamás , Joseph, Nitin , Joukar, Farahnaz, Jürisson, Mikk , Kalankesh, Leila R , Kalhor, Rohollah , Kalkonde, Yogeshwar , Kamath, Ashwin , Al-Salihi, Nawzad Kameran, Kandel, Himal , Kapoor, Neeti , Kasa, Ayele Semachew , Keshavarz, Pedram , Keykhaei, Mohammad , Khader, Yousef , Khalilov, Rovshan , Khan, Maseer , Khan, Md Nuruzzaman , Khan, Moien AB , Khang, Young-Ho, Khater, Amir M, Kısa, Adnan , Kısa, Sezer , Kopec, Jacek A , Koteeswaran, Rajasekaran , Koul, Parvaiz A , Laxminarayana, Sindhura Lakshmi Koulmane , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, G Anil , Kurmi, Om , Kutluk, Tezer, Lami, Faris Hasan, Lee, Yo Han , Leigh, James , Leong, Elvynna , Li, Ming‐Chieh , Liu, Xuefeng , Loureiro, Joana A. , Lunevičius, Raimundas , Razek, Muhammed Magdy Abd El, Majeed, Azeem , Makki, Alaa, Male, Shilpa, Malik, Ahmad Azam , Martini, Santi , Masoumi, Seyedeh Zahra , Mehrotra, Ravi , Mendoza, Walter, Mengesha, Endalkachew Worku , Mesregah, Mohamed Kamal , Jonasson, Junmei Miao , Miazgowski, Bartosz , Miazgowski, Tomasz , Michałek, Irmina Maria , Miller, Ted R. , Mirzaei, Hamid Reza , Misra, Sanjeev , Mithra, Prasanna , Moghadaszadeh, Masoud, Mohammad, Karzan Abdulmuhsin , Mohammad, Yousef , Mohammadi, Mokhtar , Mohammadi, Seyyede Momeneh, Mohammadian-Hafshejani, Abdollah , Mohammed, Shafiu , Moka, Nagabhishek , Mokdad, Ali H. , Molokhia, Mariam , Monasta, Lorenzo , Moosavi, Mohammad Amin , Moradi, Yousef , Moraga, Paula , Morgado-da-Costa, Joana, Mubarik, Sumaira , Mwanri, Lillian , Nagarajan, Ahamarshan Jayaraman , Nagata, Chie , Naimzada, Mukhammad David , Nangia, Vinay, Naqvi, Atta Abbas , Swamy, Sreenivas Narasimha, Negoi, Ionuţ , Negru, Șerban , Kandel, Sandhya Neupane , Nguyen, Cuong Tat , Niazi, Robina Khan, Nnaji, Chukwudi A , Noor, Nurulamin M , Nzoputam, Chimezie Igwegbe , Oancea, Bogdan , Ogbo, Felix Akpojene , Olagunju, Andrew T , Olakunde, Babayemi O. , Omar, Emad, Bali, Ahmed Omar , Omonisi, Abidemi , Ong, Sokking, Onwujekwe, Obinna , Ortega-Altamirano, Doris V , Otstavnov, Stanislav S , Mahesh, P A , Pakshir, Keyvan , Pană, Adrian , Panagiotakos, Demosthenes B. , Panda‐Jonas, Songhomitra, Park, Eun‐Cheol , Park, Eun‐Kee , Kan, Fatemeh Pashazadeh , Patel, Harsh K. , Patel, Jenil , Pati, Siddhartha , Paudel, Uttam , Pereira, David M. , Pereira, Renato B. , Perianayagam, Arokiasamy , Pillay, Julian David , Pirouzpanah, Saeed , Podder, Indrashis , Postma, Maarten J. , Prashant, Akila , Preoțescu, Liliana , Rabiee, Navid , Radfar, Amir , Radhakrishnan, Raghu , Radhakrishnan, Venkatraman , Rahim, Fakher , Rahimzadeh, Shadi , Rahman, Mosiur , Rahman, Muhammad Aziz , Rajai, Nazanin , Rajesh, Aashish , Ram, Pradhum , Ramezanzadeh, Kiana, Ranabhat, Kamal , Rao, Chythra R , Rao, Sowmya J, Rawassizadeh, Reza , Razeghinia, Mohammad Sadegh , Rezapour, Aziz, Buendía, Jefferson Antonio , Rohloff, Peter , Rwegerera, Godfrey Mutashambara , Manjula, S, Saddik, Basema , Saeed, Umar , Sahoo, Harihar , Salehi, Sana , Salem, Marwa Rashad , Samaei, Mehrnoosh, Samy, Abdallah M , Sanabria, Juan , Sankararaman, Senthilkumar , Santric-Milicevic, Milena M , Sardiwalla, Yaeesh , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Šekerija, Mario , Seylani, Allen, Shafaat, Omid , Shaikh, Masood Ali , Shannawaz, Mohammed , Sheikhbahaei, Sara , Shetty, Adithi , Shetty, Jeevan K. , Shetty, Pavanchand H, Shirkoohi, Reza , Shivarov, Velizar , Malleshappa, Sudeep K Siddappa , Silva, Diego Augusto Santos , Sintayehu, Yitagesu , Skryabin, Valentin Yurievich , Soeberg, Matthew, Sofi‐Mahmudi, Ahmad , Steiropoulos, Paschalis , Straif, Kurt, Subedi, Ranjeeta , Sultana, Saima , Szerencsés, Viktória , Tabuchi, Takahiro , Tadbiri, Hooman , Takahashi, Ken , Tan, Ker‐Kan , Tat, Vivian Y, Tedla, Bemnet , Tefera, Yonas Getaye , Temsah, Mohamad‐Hani , Tesfay, Fisaha Haile , Tessema, Gizachew Assefa , Thavamani, Aravind , Chandrasekar, Viveksandeep Thoguluva , Touvier, Mathilde , Tovani‐Palone, Marcos Roberto , Traini, Eugenio , Tran, Mai Thi Ngoc , Tripathy, Jaya Prasad , Tusa, Biruk Shalmeno , Ullah, Irfan , Ullah, Saif , Umapathi, Krishna Kishore , Vaezi, Maryam, Tahbaz, Sahel Valadan , Velazquez, Diana Zuleika , Violante, Francesco Saverio , Volovici, Victor , Vu, Giang Thu , Waheed, Yasir , Ward, Paul , Wen, Yi Feng , Westerman, Ronny, Yadav, Lalit , Jabbari, Seyed Hossein Yahyazadeh, Yang, Lin , Yazie, Taklo Simeneh , Yeshaw, Yigizie , Younis, Mustafa Z , Yousefi, Zabihollah , Yunusa, Ismaeel , Zadnik, Vesna , Zare, Fariba , Застрожин, Михаил Сергеевич , Zastrozhina, Anasthasia, Zhang, Jianrong , Zhong, Chenwen, Zhu, Cong , Zimmermann, Ivan Ricardo , Fitzmaurice, Christina , Murray, Christopher J L , Force, Lisa M , Ong, Sok King , Eftekhari, Aziz , Guimarães, André Luiz Sena , Kumar, Vivek , Lami, Faris , Liu, Xuefeng , Baig, Atif Amin , Thoguluva Chandrasekar, Viveksandeep, Kumar, Vivek , Cao, Yin , Brenner, Hermann , Farzadfar, Farshad , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Guha, Avirup , Ebrahimi, Hedyeh , Volovici, Victor , Bhagavathula, Akshaya Srikanth , Jakovljević, Mihajlo , Elhadi, Muhammed , Abdoli, Amir , Adnani, Qorinah Estiningtyas Sakilah , Afzal, Muhammad Sohail, Ahinkorah, Bright Opoku , Ahmad, Sajjad , Ahmadi, Ali , Ahmadi, Sepideh , Akalu, Gizachew Taddesse , Al‐Aly, Ziyad , Ali, Saqib , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Anbesu, Etsay Woldu , Ancuceanu, Robert , Ansari‐Moghaddam, Alireza , Arab-Zozani, Morteza , Asemi, Zatollah , Aujayeb, Avinash , Azzam, Ahmed Y , Banach, Maciej , Barra, Fabio , Behzadifar, Masoud , Bezabhe, Woldesellassie M Mequanint , Bhardwaj, Pankaj , Bhattacharyya, Krittika , Biondi, Antonio , Bjørge, Tone , Bleyer, Archie , Blyuss, Oleg B. , Chaturvedi, Pankaj, Christopher, Devasahayam Jesudas , Chung, Michael T. , Cortesi, Paolo Angelo , Belachew, Amare , Dahlawi, Saad M A , Dai, Xiaochen , Darwesh, Aso Mohammad , Neves, José das , Demis, Asmamaw , Denova‐Gutiérrez, Edgar , Dhimal, Meghnath , Dianatinasab, Mostafa , Do, Huyen Phuc , Doaei, Saeid , Figueiredo, Francisco Winter dos Santos , El-Jaafary, Shaimaa I , Eskandarieh, Sharareh , Faraon, Emerito Jose A , Ferrero, Simone , Filip, Irina , Foroutan, Masoud , Gaál, Péter , Gadanya, Muktar A , Gallus, Silvano , Gomez, Ricardo Santiago , Grosso, Giuseppe , Gupta, Veer Bala , Haj‐Mirzaian, Arvin , Halwani, Rabih , Hamadeh, Randah R , Hamidi, Samer , Haro, Josep María , Hassanipour, Soheil , Hay, Roderick J. , Hayat, Khezar , Heidari, Mohammad , Holla, Ramesh , Hossain, Md Mahbub , Hostiuc, Sorin , Iavicoli, Ivo , Ilesanmi, Olayinka Stephen , Ilić, Milena , Islam, Rakibul M. , Jazayeri, Seyed Behzad , Kabir, Ali , Kahrizi, Danial , Kaliyadan, Feroze , Karch, André , Katikireddi, Srinivasa Vittal , Kauppila, Joonas H. , Kavetskyy, Taras , Kebede, Sewnet Adem , Khan, Gulfaraz , Khang, Young-Ho, Khayamzadeh, Maryam , Kim, Gyu Ri , Kim, Yun Jin , Kissimova‐Skarbek, Katarzyna , Koyanagi, Ai , Kumar, Narinder , Kumar, Nithin , Vecchia, Carlo La , Landires, Iván , Lauriola, Paolo , Lee, Sang Hyuck , Lee, Shaun Wen Huey , Lee, Wei‐Chen , Li, Jiarui , Mansournia, Mohammad Alì , Mathur, Prashant , McKee, Martin , Menezes, Ritesh G. , Meštrović, Tomislav , Mirzaei, Hamed , Moni, Mohammad Ali , Morrison, Shane D. , Mosapour, Abbas , Nagaraju, Shankar Prasad , Ndejjo, Rawlance , Nduaguba, Sabina O. , Nguyen, Huong Lan Thi , Núñez-Samudio, Virginia , Оchir, Chimedsuren , Odukoya, Oluwakemi Ololade , Ong, Sokking, Orru, Hans , Otstavnov, Nikita , Owolabi, Mayowa , Padubidri, Jagadish Rao , Pardhan, Shahina , Pattanshetty, Sanjay M. , Pishgar, Farhad , Pourjafar, Hadi , Rabiee, Mohammad , Rafiee, Ata , Rahmani, Amir Masoud , Rakovac, Ivo , Ranasinghe, Priyanga Diloshini , Renzaho, André M. N. , Rezaei, Negar , Rezaei, Nima , Roberts, Thomas J. , Romoli, Michele , Ronfani, Luca , Roshandel, Gholamreza , Sabour, Siamak , Sahebkar, Amirhossein , Salimzadeh, Hamideh , Şaylan, Mete , Schneider, Ione Jayce Ceola , Shaghaghi, Zahra , Shamsoddin, Erfan , Sharma, Rajesh , Sheikh, Aziz , Shibuya, Kenji , Shivakumar, K. M. , Siabani, Soraya , Singh, Jasvinder A. , Skryabina, Anna Aleksandrovna , Sotoudeh, Houman , Sufiyan, Mu’awiyyah Babale , Sultan, Iyad Yasin , Sur, Daniel Genel , Szócska, Miklós , Tabarés‐Seisdedos, Rafael , Taherkhani, Amir , Talaat, Iman Mamdouh , Tehrani‐Banihashemi, Arash , Thapar, Rekha , Thomas, Nihal , Tohidinik, Hamid Reza , Tran, Bach Xuan , Tran, Khanh Bao , Unnikrishnan, Bhaskaran , Upadhyay, Era , Vacante, Marco , Vaezi, Maryam, Veroux, Massimiliano , Vlassov, Vasily , Vo, Bay, Wamai, Richard G. , Winkler, Andrea Sylvia , Yaya, Sanni , Yonemoto, Naohiro , Yu, Chuanhua , Yüce, Deniz , Zhou, Linghui , Ziapour, Arash , Olagunju, Andrew T , Shivakumar, KM , Baig, Atif Amin , Alahdab, Fares , Asghari-Jafarabadi, Mohammad , Rahim, Fakher

Mayo Clinic

JAMA Oncology | December 30, 2021 | Volume: 8 | Issue: 3 | Pages: 420

10.1001/jamaoncol.2021.6987 | PMID 34967848 Get It

Association of transcatheter edge-to-edge repair with improved survival in older patients with severe, symptomatic degenerative mitral regurgitation
Benfari, Giovanni , Sorajja, Paul , Pedrazzini, Giovanni , Taramasso, Maurizio , Gavazzoni, Mara , Biasco, Luigi , Essayagh, Benjamin , Grigioni, Francesco , Bae, Richard , Tribouilloy, Christophe , Bapat, Vinayak , Vancraynest, David, Curti, Moreno , Thapa, Prabin , Vancraeynest, David , Vanoverschelde, Jean-Louis , Michelena, Hector I , Bapat, Vinayak N , Klersy, Catherine , Curti, Moreno , Thapa, Prabin , Enriquez-Sarano, Maurice , Benfari, Giovanni , Essayagh, Benjamin , Sorajja, Paul , Vanoverschelde, Jean‐Louis , Michelena, Héctor I. , Klersy, Catherine , Enriquez‐Sarano, Maurice , Grigioni, Francesco

Mayo Clinic

European Heart Journal | December 27, 2021 | Volume: 43 | Issue: 17 | Pages: 1626-1635

10.1093/eurheartj/ehab910 | PMID 35090000 Get It

Abstract Background Randomized clinical trials demonstrated transcatheter edge-to-edge repair (TEER) efficacy in improving outcome vs. medical management for functional mitral regurgitation, but limited randomized data are available for the treatment of degenerative mitral regurgitation (DMR). We aimed to compare the outcome of older patients treated with TEER vs. unoperated DMR. Methods and results Registries including consecutive patients ≥65 years with symptomatic severe DMR treated with TEER (MitraSwiss and Minneapolis Heart Institute registries) or unoperated (MIDA registry) were analysed. Survival was compared overall and after matching for age, sex, EuroSCORE II, and ejection fraction. The study included 1187 patients (872 treated with TEER and 315 unoperated). During 24 ± 17 months of follow-up, 430 patients died, 18 ± 1% at 1 year and 50 ± 2% at 4 years. Patients undergoing TEER had similar age (82 ± 6 vs. 82 ± 7 years) and sex to unoperated patients, but higher surgical risk/comorbidity (EuroSCORE II 3.98 ± 4.28% vs. 2.77 ± 2.46%), more symptoms, and atrial fibrillation (P &lt; 0.0001). Transcatheter edge-to-edge repair was associated with lower mortality accounting for age, sex, EuroSCORE II, New York Heart Association class, atrial fibrillation, and ejection fraction [hazard ratio (HR): 0.47, 95% confidence interval (CI): 0.37–0.58; P &lt; 0.0001]. After propensity matching (247 pairs of patients), TEER consistently showed better survival compared with unoperated patients (49 ± 6% vs. 37 ± 3% at 4 years, P &lt; 0.0001) even in comprehensive multivariable analysis (HR: 0.60, 95% CI: 0.40–0.91; P = 0.03). Procedural failure was infrequent but post-procedural mitral regurgitation, remaining moderate-to-severe in 66 (7.6%) patients, was associated with excess mortality vs. trivial residual regurgitation (30 ± 6% vs. 11 ± 1% at 1 year, P &lt; 0.0001). Conclusion Amongst older patients with severe symptomatic DMR at high surgical risk, mitral TEER was associated with higher survival vs. unoperated patients. Successful control of mitral regurgitation was key to survival improvement with mitral TEER, which should be actively considered in patients deemed inoperable.
Exome Sequencing Highlights a Potential Role for Concealed Cardiomyopathies in Youthful Sudden Cardiac Death
Neves, Raquel , Tester, David J. , Simpson, Michael A. , Behr, Elijah R. , Ackerman, Michael J. , Giudicessi, John R. , Behr, Elijah Raphael , Neves, Raquel Almeida Lopes , Neves, Raquel, Tester, David J, Simpson, Michael A, Behr, Elijah R, Ackerman, Michael J, Giudicessi, John R

Mayo Clinic

Circulation: Genomic and Precision Medicine | December 24, 2021 | Volume: 15 | Issue: 1 | Pages: No page available

10.1161/circgen.121.003497 | PMID 34949102 Get It

Background: Sudden cardiac arrest (SCA) and sudden unexplained death (SUD) are feared sequelae of many genetic heart diseases. In rare circumstances, pathogenic variants in cardiomyopathy-susceptibility genes may result in electrical instability leading to SCA/SUD before any structural manifestations of underlying cardiomyopathy are evident. Methods: Collectively, 38 unexplained SCA survivors (21 males; mean age at SCA 26.4±13.1 years), 68 autopsy-inconclusive SUD cases (46 males; mean age at death 20.4±9.0 years) without disease-causative variants in the channelopathy genes, and 973 ostensibly healthy controls were included. Following exome sequencing, ultrarare (minor allele frequency ≤0.00005 in any ethnic group within Genome Aggregation Database [gnomAD, N=141 456 individuals]) nonsynonymous variants identified in 24 Clinical Genome Resource adjudicated definitive/strong evidence cardiomyopathy-susceptibility genes were analyzed. Eligible variants were adjudicated as pathogenic, likely pathogenic, or variant of uncertain significance in accordance with current American College of Medical Genetics and Genomics guidelines. Results: Overall, 7 out of 38 (18.4%) SCA survivors and 14 out of 68 (20.5%) autopsy-inconclusive, channelopathic-negative SUD cases had at least one pathogenic/likely pathogenic or a variant of uncertain significance nonsynonymous variant within a strong evidence, cardiomyopathy-susceptibility gene. Following American College of Medical Genetics and Genomics criterion variant adjudication, a pathogenic or likely pathogenic variant was identified in 3 out of 38 (7.9%; P =0.05) SCA survivors and 8 out of 68 (11.8%; P =0.0002) autopsy-inconclusive SUD cases compared to 20 out of 973 (2.1%) European controls. Interestingly, the yield of pathogenic/likely pathogenic variants was significantly greater in autopsy-inconclusive SUD cases with documented interstitial fibrosis (4/11, 36%) compared with only 4 out of 57 (7%, P <0.02) SUD cases without ventricular fibrosis. Conclusions: Our data further supports the inclusion of strong evidence cardiomyopathy-susceptibility genes on the genetic testing panels used to evaluate unexplained SCA survivors and autopsy-inconclusive/negative SUD decedents. However, to avoid diagnostic miscues, the careful interpretation of genetic test results in patients without overt phenotypes is vital.
The year in cardiovascular medicine 2021: cardio-oncology
Herrmann, Joerg , López‐Fernández, Teresa , Lyon, Alexander R. , López-Fernández, Teresa , Lyon, Alexander R

Mayo Clinic

European Heart Journal | December 21, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/eurheartj/ehab891 | PMID 34974609 Get It